저위험 유관 상피내암종(DCIS)에서 단독 유방 보존 수술의 전향적 평가 (ELISA)
임상-병리학적 특징과 결합된 분자 발현 분석에 의해 정의된 저위험 유관 암종에서 단독 유방 보존 수술의 전향적 평가
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
연구 개요
상태
상태
정황
정황
상세 설명
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.
At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.
Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
연구 유형
연구 유형
등록 (추정된)
등록
연락처 및 위치
연구 장소
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2N 5G2
- Arthur J.E. Child Comprehensive Cancer Centre
-
Edmonton, Alberta, 캐나다, T6G 1Z2
- Cross Cancer Institute
-
-
British Columbia
-
Abbotsford British Columbia, British Columbia, 캐나다, V2S 0C2
- BC Cancer - Abbotsford Centre
-
Prince George, British Columbia, 캐나다, V2M 7E9
- BC Cancer - Centre for the North (Prince George)
-
Surrey, British Columbia, 캐나다, V3V 1Z2
- BC Cancer - Fraser Valley Centre
-
Vancouver, British Columbia, 캐나다, V5Z 4E6
- BC Cancer - Vancouver Centre
-
Victoria, British Columbia, 캐나다, V8R 6V5
- BC Cancer - Victoria
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3H 1V7
- QE II HSC - Nova Scotia Cancer Centre
-
Sydney, Nova Scotia, 캐나다, B1P 1P3
- Cape Breton Cancer Centre
-
-
Ontario
-
Barrie, Ontario, 캐나다, L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton, Ontario, 캐나다, L8V 5C2
- Juravinski Cancer Centre
-
London, Ontario, 캐나다, N6A 4L6
- London Regional Cancer Program
-
Thunder Bay, Ontario, 캐나다, P7B 6V4
- Regional Cancer Care, Thunder Bay Regional Health Sciences Centre
-
Toronto, Ontario, 캐나다, M4N 3M5
- Sunnybrook Health Science Centre -Odette Cancer Centre
-
Toronto, Ontario, 캐나다, M5G 2M9
- University Health Network - Princess Margaret Cancer Centre
-
Windsor, Ontario, 캐나다, N8W 2X3
- Windsor Regional Cancer Centre
-
-
Quebec
-
Greenfield Park, Quebec, 캐나다, J4V 2H1
- Hôpital Charles Le Moyne (CISSS de la Montérégie-Centre)
-
Montreal, Quebec, 캐나다, H4A 3J1
- McGill University Health Centre
-
Montreal, Quebec, 캐나다, H2L 4M1
- CHUM - Centre Hospitalier de L'Université de Montréal
-
Québec, Quebec, 캐나다, G1J 1Z4
- Centre intégré de cancérologie du CHU de Québec - Université Laval
-
Trois-Rivières, Quebec, 캐나다, G8Z 3R9
- Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie- Centre-du-Québec (CIUSSS MCQ) - Trois-Rivières
-
-
Saskatchewan
-
Regina, Saskatchewan, 캐나다, S4T 7T1
- Allan Blair Cancer Centre
-
Saskatoon, Saskatchewan, 캐나다, S7N4H4
- Saskatoon Cancer Centre
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.
Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment
설명
Inclusion Criteria:
-
Female patient > 45 years of age with DCIS without microinvasion.
-
Tumour size ≤ 2.5cm.
-
Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*
* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.
-
Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion Criteria:
- Multifocal DCIS.
- History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
- Synchronous or previous invasive or non-invasive breast cancer.
- Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
- ECOG performance status ≥3.
- Life expectancy <10 years.
- Geographic inaccessibility for follow-up.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
그룹/코호트 수
코호트 및 개입
그룹/코호트그룹/코호트 |
|---|
|
Single Arm Cohort
Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Ipsilateral local recurrence (LR)
기간: 5 Year
|
Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
5 Year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Ipsilateral invasive local recurrence
기간: 5 Year
|
defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
5 Year
|
|
Breast cancer recurrence-free interval (RFI)
기간: 5 Year
|
defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
5 Year
|
|
Distant disease-free survival (DDFS)
기간: 5 Year
|
defined as time from study registration to distant recurrence |
5 Year
|
|
Disease-free survival (DFS)
기간: 5 Year
|
defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
5 Year
|
|
Overall survival (OS)
기간: 5 Year
|
defined as time from registration to death of any cause |
5 Year
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Eileen Rakovitch, M.D., Sunnybrook Research Institute, Sunnybrook Health Science
- 수석 연구원: Tim Whelan, M.D, Juravinski Cancer Centre
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- OCOG-2021-ELISA
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .